Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.

Teppei OkamotoDaisuke NoroShingo HatakeyamaShintaro NaritaKoji MitsuzukaToshihiko SakuraiSadafumi KawamuraSenji HoshiJiro ShimodaToshikazu TanakaToshiaki KawaguchiShigeto IshidoyaAkihiro ItoNorihiko TsuchiyaTomonori HabuchiChikara Ohyama

Published in: BMC cancer (2021)

Pretreatment anemia was a prognostic factor among mHSPC patients who received upfront ABI. Although the upfront ABI significantly improved the PFS of mHSPC patients without anemia, its efficacy in patients with anemia might be limited.

Keyphrases

chronic kidney disease
prognostic factors
end stage renal disease
iron deficiency
prostate cancer
ejection fraction
squamous cell carcinoma
newly diagnosed
radical prostatectomy
peritoneal dialysis
clinical trial